{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-035948","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2022-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.798706+00:00","generated_at":"2026-06-21T02:14:21.739459+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ProPhase Labs to acquire Stella Diagnostics' BE-Smart esophageal cancer test for approx $4.5M","bullets":["Total consideration ~$4.5M ($3.5M cash + 100k shares of PRPH common stock); up to $2M additional PRPH shares upon commercial milestone.","BE-Smart test showed >99% sensitivity/specificity on >200 human samples; aims for commercialization within 18 months.","Target market: Barrett's esophagus affects 3-6M US patients; potential reimbursement $1,000–$3,000 per test.","Transaction expected to close early January 2023, subject to Stella shareholder approval.","Stella to receive 5% royalty on adjusted gross margin from commercialized IP."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-035948","json":"https://secwatch.observer/filing/0001493152-22-035948.json","markdown":"https://secwatch.observer/filing/0001493152-22-035948.md","text":"https://secwatch.observer/filing/0001493152-22-035948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315222035948/0001493152-22-035948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315222035948/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:14:21.739459+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fec6fbcbbb760cdd74b7fd8bfa85ef7349583eba","claim":"ProPhase Labs, Inc. entered into Asset Purchase Agreement with Stella Diagnostics Inc. and Stella DX, LLC valued at $3,486,000 in cash (effective 2022-12-15).","evidence_excerpt":"On December 15, 2022, ProPhase Labs, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), by and among the Company and Stella Diagnostics Inc. (“Stella”) and Stella DX, LLC (“Stella DX” and, together with Stella, the “Sellers”), pursuant to which the Company will purchase all of the assets, rights and interests of the Sellers and their affiliates pertaining to the Sellers’ BE-Smart Esophageal Pre-Cancer diagnostic screening test and certain clinical assets, including all intellectual property rights (the “Purchased Assets”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315222035948/0001493152-22-035948-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Stella Diagnostics Inc. and Stella DX, LLC"},{"label":"Value","value":"$3,486,000 in cash"},{"label":"Effective","value":"2022-12-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}